The Commission on Future Research Priorities in the USA sets out 13 key priority areas to help focus the $2 billion of funding released to the NCI.
The BCL-2 inhibitor venetoclax had an acceptable safety profile and showed evidence of activity in patients with relapsed/refractory multiple myeloma.
Combination treatment with a novel CXCR4 inhibitor and axitinib resulted in an encouraging overall response rate and disease control rate in patients with clear cell renal cell carcinoma, according to the results from phase I of a phase I/II trial.
Older patients with acute myeloid leukemia had substantial misperceptions regarding the risks of their treatment, whether intensive or palliative chemotherapy, and the likelihood of cure.
Use of a single-day multidisciplinary clinic visit allowed for more efficient and comprehensive cancer care in a group of patients with head and neck cancer, according to the results of a new study.
HER3 messenger RNA expression may serve as a biomarker for patients with RAS wild type colorectal cancer who will benefit from treatment with the anti-EGFR therapy panitumumab, according to the results of a new study.
A combination of oral antibiotics and mechanical bowel preparation helped to decrease the rate of surgical site infections in patients undergoing rectal cancer resections.
Children with relapsed or refractory INI1-deficient malignant rhabdoid tumors, epithelioid sarcomas, or poorly differentiated chordomas tolerated treatment with the investigational drug tazemetostat well, including several responses.
When presented with different options, patients perceived physicians that communicated face to face without the use of a computer as being more compassionate, professional, and as having better communication skills.
The number of extranodal sites of disease did not influence outcomes among young patients with high-risk DLBCL treated with rituximab-dose-dense chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation.